Syverson Strege & Co’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Syverson Strege & Co’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-25	Closed	-$2.73K	–	663
2023 Q1	$2.73K	Buy	+25	New	+$2.76K	﹤0.01%	429
2021 Q4	–	Sell	-46	Closed	-$5K	–	502
2021 Q3	$5K	Buy	+46	New	+$4.78K	﹤0.01%	335

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

HBK Investments Dallas, Texas $10.3B AUM 67.69% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Syverson Strege & Co's HZNP Position: Q2 2023 in Review

Syverson Strege & Co sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q2 2023, closing a stake of 25 shares — an estimated $2.73K sold.

Syverson Strege & Co first reported a position in HZNP in Q3 2021 and held it in 2 quarters. The position peaked at $5K in Q3 2021. 517 funds tracked by Wall St. Rank hold HZNP as of Q2 2023.

Syverson Strege & Co reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q2 2023 after selling out during the quarter.
Syverson Strege & Co sold 25 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q2 2023, an estimated $2.73K.
Syverson Strege & Co first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2021 and held it in 2 quarters.
Syverson Strege & Co's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $5K in Q3 2021.
517 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q2 2023.

Based on Syverson Strege & Co's 13F filing for Q2 2023, filed 4 Aug 2023.